bones. [10] The RUNX2 gene has been mapped to chromosome 6p21 and consists of several established functional domains. The Runt domain, an evolutionary conserved polypeptide motif located in the N-terminal of RUNX2, mediates DNA binding and protein-protein interaction, including heterodimerization with the core-binding factor subunit beta. [11] Adjacent to the Runt domain is the nuclear localization signal, which accumulates RUNX2 in the cell nucleus. [12, 13] Furthermore, RUNX2 possesses a Q/A domain with glutamine and alanine repeats, [14] and the C-terminus consists of a transactivation proline-serine-threonine-rich (PST) domain with abundant PST. [7] The nuclear matrix-targeting signal (NMTS) is necessary for subnuclear localization and protein binding in the middle of the PST domain. [15, 16] The Val-Trp-Arg-Pro-Tyr (VWRPY) peptide that supports transcriptional repression comprises the last section of the C-terminal.
RUNX2 mutation is not observed in approximately 30% of CCD patients. [12] Previous studies have identified over eighty heterozygous RUNX2 mutations in CCD patients. [4, 13, 17, 18] RUNX2 mutations are generally located in the Runt domain, most of which are missense mutations. Only 10% of the C-terminal mutations are missense mutations. [18, 19] In the present study, we identified a novel RUNX2 mutation: c.1111dupT (p.Ser371PhefsX14), in a sporadic case.
meThods

Patient selection
A Chinese individual who presented with clinical symptoms of CCD was recruited. The Ethical Committee of Peking University School and Hospital of Stomatology (PKUSSIRB-201627028) approved the study. Informed consent was obtained from the patient.
Genetic testing
Up to 3 ml of peripheral blood was drawn from the CCD-affected patient and stored in an anticoagulation tube containing ethylenediaminetetraacetic acid (EDTA). Genomic DNA extraction from the whole blood of the patient was conducted with QIAamp ® DNA Blood Kit (Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions. Exons 1-8 of the RUNX2 gene were amplified by polymerase chain reaction (PCR) using previous combinations of primers. [13] PCR amplifications were performed in a thermal cycler (PE 2400, Life Technologies, Carlsbad, California, USA) with 50 µl reaction volumes. Sequencing was performed at Life Technologies, Inc., Shanghai, China.
Plasmid DNA and mutagenesis
Plasmid vector coding-enhanced green fluorescent protein (EGFP): pEGFP-C1-vector and pEGFP-C1-RUNX2 plasmids were purchased from Youbio (Changsha, China). pEGFP-C1-RUNX2 plasmid was PCR amplified using human embryonic kidney (HEK) 293T cDNA as the template and then cloned into the pEGFP-C1-vector between KpnI/SacII sites. The primers are 5'-ACTCTCGAGATGGCATCAAACAGCCTCTT-3' ( f o r w a r d ) a n d 5 ' -A C T C C G C G G T C A ATAT GGTCGCCAAACAG-3' (reverse). The amino acid duplication of RUNX2 mutation was accomplished by PCR amplification using pEGFP-C1-RUNX2 circular plasmid as the template, 5'-AACTGGGCCCTTTT TTCAGACCCCAGG-3' as the forward primer, and 5'-CCTGGGGTCTGAAAAAAGGGCCCAGTT-3' as the reverse primer. The construct was completely sequenced and used as the template in other cloning designs.
Cell culture
HEK293T cells were cultured in Dulbecco's Modified Eagle's Medium (HyClone, Logan, USA) supplemented with 100 mg/ml streptomycin and penicillin, and 10% fetal bovine serum (HyClone, Logan, UT, USA), and then incubated in 95% air and 5% CO 2 at 37°C.
Western blotting analysis
HEK293T cells were seeded and transiently transfected with pEGFP-C1-vector, pEGFP-C1-RUNX2, and pEGFP-C1-RUNX2-mut, using Vigo Transfection Reagent.
Cells were lysed in Tris-HCl (pH 7.4), NaCl, and EDTA (TNE) buffer plus protease inhibitor cocktail (Roche Applied Science, Basel, Switzerland) at 4°C for 30 min. These supernatants were resolved through SDS-PAGE gel electrophoresis after centrifugation. The anti-GFP antibody was used (Santa Cruz, Dallas, USA).
In situ immunofluorescence microscopy
pEGFP-C1-RUNX2 and pEGFP-C1-RUNX2-mut plasmids were separately transfected into HEK293T cells and then cultured for 24 h. Afterward, the cells were processed and washed three times with phosphate-buffered saline (PBS) and 0.1% triton X-100 for 5 min each. The cells were fixed with 4% paraformaldehyde, washed three times with PBS, and then incubated with Goat Anti-mouse IgG conjugated with Alexa Fluor 555 for 1 h at room temperature. Prolong ® Gold Antifade Reagent (Invitrogen, Carlsbad, California, USA) was used to mount the cover slides following three times washing with PBS. A Zeiss LSM710 (Carl Zeiss, Oberkochen, Germany) was used to capture immunofluorescent signals.
Transient transfection and osteocalcin promoter luciferase assay
HEK293T cells were seeded in 24-well plates one day before transfection. Cells at 60%-80% confluence were transfected in 50 µl of Vigo Transfection Reagent. The pRenilla-TK vector was used as an internal control. After 48 h of transfection, the cells were collected and measured using the luciferase assay system (Promega, Madison, Wisconsin, USA).
Statistical analysis
All experiments were repeated at least three times. Results were expressed as mean ± standard deviation (SD). SPSS software (IBM SPSS Statistics, version 20.0, IBM Corporation, Armonk, New York, USA) was used for statistical analysis. Results were examined by Student's t-test. Statistical significance was considered at P < 0.05.
resUlTs
Clinical findings
An 18-year-old female came to the hospital with a chief complaint of multiple impacted teeth. The patient showed typical clinical symptoms of CCD, including a concave profile and short stature (141 cm high). However, no abnormal hypermobility of the shoulders was found [ Figure 1a and 1b]. The patient did not have any family history of this disease.
Oral manifestations and radiographic features
Oral manifestations include an edge-to-edge occlusion of the anterior teeth, retention of deciduous teeth, and a high-arched palate with a median pseudocleft [ Figure 1c ]. The 18-year-old patient had merely five permanent teeth (16, 14, 11, 26 , and 36) erupted on her first visit.
Chest posterioanterior view revealed a bell-shaped thoracic cage and short and thick clavicles [ Figure 1d ]. Anteroposterior radiography revealed a plastic frontal sinus, Wormian bone, and dysplastic zygomatic bone [ Figure 1e ]. These symptoms were also previously observed in a CCD patient with T420I mutation in the PST domain. [20] The lateral cephalogram developed from cone beam computed tomography (CBCT) showed maxillary hypoplasia [ Figure 1g ]. The panoramic radiography developed from CBCT confirmed deciduous teeth retention, permanent teeth impaction, and delayed development with abnormal roots and multiple supernumerary teeth. It also revealed the parallel-sided anterioposterior borders of the ascending ramus, slender and pointed coronoid process facing upward, thin zygomatic arch and increased bone density between the anterior border of the ascending ramus and the inferior dental canal [ Figure 1f ]. The symptoms are consistent with those in the previous study. [3] Mutation analysis A novel single-base pair duplication: c.1111dupT in exon 8 was detected in the patient [ Figure 2a ], causing a frameshift mutation ending at the consequent premature stop codon 384, which led to a truncated RUNX2 protein comprising merely 383 amino acids. The result was confirmed by Western blot analysis [ Figure 2b ]. The NMTS region was involved in this mutation.
Nuclear localization of runt-related transcription factor 2 mutation
RUNX2 is localized in the cell nucleus and perinucleolar region. [14, 21, 22] The NMTS-associated subnuclear foci of RUNX2 are responsible for the transactivation of the osteoblast-specific osteocalcin gene in osseous cells. [14] To identify the nuclear localization of the RUNX2 mutation, we transfected both pEGFP-C1-RUNX2 and pEGFP-C1-RUNX2-mut plasmids into HEK293T cells. The subcellular localization of the wild-type RUNX2 and the mutation was observed by in situ immunofluorescence microscopy.
The RUNX2 mutation and wild-type RUNX2 accumulated in the nuclei of HEK293T cells [ Figure 3 ]. However, the RUNX2 mutation was also observed in the perinuclear region and cytoplasm, which indicated that the subcellular compartmentalization of the RUNX2 mutation was partially perturbed.
Transcription activation's abilities
To examine the effect of the RUNX2 proteins on the transactivation activity of HEK293T cells, we conducted DNA co-transfection experiments in HEK293T cells with the RUNX2-responsive osteocalcin promoter (p6OSE2-luc) as the reporter. Wild-type RUNX2 increased the promoter 
discUssion
In the current study, we confirmed a novel RUNX2 mutation in a sporadic Chinese patient with symptoms of CCD. The mutation leading to a frameshift from codon 371 to the premature stop codon 384 is responsible for the haploinsufficiency of RUNX2, and therefore causes the disease. The RUNX2 mutation resulted in the absence of the NMTS domain and C-terminal pentapeptide VWRPY.
The NMTS near the C-terminal of RUNX2 comprises 38 amino acids (from amino acid 397 to 434), forming a helix-loop-helix structure. [23] According to a previous study, the NMTS domain is responsible for RUNX2 retention in nuclear matrix-associated foci and important for the optimal activation of the bone-specific osteocalcin gene. [14] Interactions with SMADs, histone deacetylase 6, and Yes-associated protein might play a role in the mechanisms of the NMTS-mediating protein subnuclear distribution. [24, 25] VWRPY interacts with a Groucho/TLE/R-esp repressor protein, and osteocalcin promoter is activated through a VWRPY-dependent mechanism. [21, 26] The VWRPY domain is not important for the retention of RUNX2 in nuclear matrix-associated foci. [14] In the present study, the nuclear import of the RUNX2 mutant was partially abrogated, which does not coincide with the conclusion of Zaidi et al. [14] The perinuclear leak of RUNX2 mutant expression might explain its decreased ability in activating downstream genes as shown in the results of the luciferase assay. The decreased ability could be partly modified by increasing the dose of the RUNX2 mutant plasmid, implying a correlation between the dosage and the abrogated function of the RUNX2 mutant.
CCD has a wide spectrum of clinical symptoms. According to the OMIM, CCD is related to over 48 phenotypic features. Previous studies were performed to explain the genotype-phenotype correlation, but their results were controversial. [27] [28] [29] [30] [31] A wide variation of phenotype expressivity even within a family with identical RUNX2 mutation was observed. [28, 31] A relationship between the stature and number of supernumerary teeth was observed. [12, 31] Cunningham et al. [19] suggested that the C-terminal mutations of RUNX2 lead to a more severe phenotype because of the negative effects caused by the preservation of the Runt domain. In contrast, Bufalino et al. [29] implied a correlation between the region affected by mutations involving the Runt domain and the severity of dental phenotypes. Although the mutation was outside the Runt domain, the patient presented with severe dental abnormalities. Previous cases [32, 33] revealed frameshift mutations in similar regions: c.1116_1119insC and c.1119delC. Both mutations demonstrated extremely similar craniofacial and dental phenotypes, including retained deciduous teeth, eruption failure of permanent dentition with abnormal roots, and multiple supernumerary teeth. However, more severe clavicle problems and spina bifida occulta were observed in the previous cases than in the present case. The difference might be attributed to environmental factors and epigenetic regulation including histone modifications and DNA methylation and copy number variation.
In summary, we identified a sporadic CCD patient carrying a novel insertion/frameshift mutation of RUNX2. This finding expanded our understanding of CCD-related phenotypes. Future studies of RUNX2 mutations may provide further insights into the phenotype-genotype correlation.
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